Dimethylformamide → Rac-cis-tert-butyl 4-(2-{2-[(6-cyano-2-methylpyrimidin-4-yl)(4-methoxybenzyl)amino]ethyl}cyclopropyl)piperidine-1-carboxylate

HRID 1039050노트

반응식

HRID 1039050 반응식
I[CH2:2][CH2:3][C@H:4]1[CH2:6][C@H:5]1[CH:7]1[CH2:12][CH2:11][N:10]([C:13]([O:15][C:16]([CH3:19])([CH3:18])[CH3:17])=[O:14])[CH2:9][CH2:8]1.[OH:20][C:21]1[CH:37]=[CH:36][C:24]([CH2:25][NH:26][C:27]2[N:32]=[C:31]([CH3:33])[N:30]=[C:29]([C:34]#[N:35])[CH:28]=2)=[CH:23][CH:22]=1.[H-].[Na+].[CH3:40]N(C=O)C>>[C:34]([C:29]1[N:30]=[C:31]([CH3:33])[N:32]=[C:27]([N:26]([CH2:25][C:24]2[CH:23]=[CH:22][C:21]([O:20][CH3:40])=[CH:37][CH:36]=2)[CH2:2][CH2:3][C@H:4]2[CH2:6][C@H:5]2[CH:7]2[CH2:12][CH2:11][N:10]([C:13]([O:15][C:16]([CH3:19])([CH3:18])[CH3:17])=[O:14])[CH2:9][CH2:8]2)[CH:28]=1)#[N:35]

참가 물질

5

실험 절차

Rac-cis-tert-butyl 4-[2-(2-iodoethyl)cyclopropyl]piperidine-1-carboxylate (86 mg, 0.23 mmol) from Step 3 of this example and 6-[(4-hydroxybenzyl)amino]-2-methylpyrimidine-4-carbonitrile (63.4 mg, 0.25 mmol) from Step 2 of this example were dissolved in DMF (2.3 mL), sodium hydride (18 mg, 0.45 mmol) was added. After 10 minutes, the reaction was quenched with saturated ammonia chloride solution (5 mL), extracted with ethyl acetate (10 mL), second washed with brine (5 mL). The organic phase was dried by magnesium sulfate, filtered, concentrated and purified by preparative-TLC (Analtech Silica Gel GF 1500 μM, 20×20 cm) using 30% ethyl acetate/hexane to give the title compound as a white solid.

후처리

  1. customthe reaction was quenched with saturated ammonia chloride solution (5 mL)
  2. extractionextracted with ethyl acetate (10 mL)
  3. washsecond washed with brine (5 mL)
  4. dry with materialThe organic phase was dried by magnesium sulfate
  5. filtrationfiltered
  6. concentrationconcentrated
  7. custompurified by preparative-TLC (Analtech Silica Gel GF 1500 μM, 20×20 cm)

출처 및 근거

ORD 기록
ord-71173aacc13d495db7d2958e92b42851
출처 데이터셋
uspto-grants-2013_10
특허 번호
US08552022B2

반응 노트

불러오는 중…